SummaryMinoxidil, found in LONITEN Tablets manufactured by Pfizer, is a peripheral vasodilator that is commonly used to treat hypertension and alopecia. It works by relaxing blood vessels and increasing blood flow, which reduces blood pressure. As a potassium channel agonist and VGKCs modulator, minoxidil opens the potassium channels of smooth muscle cells in the blood vessels, allowing more potassium ions to flow out of the cells, resulting in relaxation of the vascular smooth muscle. In addition to treating hypertension, minoxidil is also used topically in solutions or foam formulations to promote hair growth and prevent further hair loss in individuals with androgenetic alopecia. |
Drug Type Small molecule drug |
Synonyms 2,4-Diamino-6-piperidinopyrimidine 3-oxide, 6-Piperidin-1-ylpyrimidine-2,4-diamine 3-oxide, Minoxidil (JAN/USP/INN) + [24] |
Target |
Mechanism ABCC9 agonists(ATP binding cassette subfamily C member 9 agonists), Kir6.2 agonists(potassium inwardly rectifying channel subfamily J member 11 agonists) |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (18 Oct 1979), |
Regulation- |
Molecular FormulaC9H15N5O |
InChIKeyZFMITUMMTDLWHR-UHFFFAOYSA-N |
CAS Registry38304-91-5 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypertension | KR | 13 Aug 2024 | |
Alopecia Areata | CN | 10 Jan 2024 | |
Alopecia | US | 17 Aug 1988 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Skin Diseases | NDA/BLA | CN | 30 Jan 2022 | |
Hypotrichosis | Phase 1 | US | 11 Mar 2023 |
Not Applicable | - | 6 | Topical Minoxidil + Microneedling | zblvwiitzn(liigbweqmq) = ghfuavbfpc lwbgtjajzb (rbbmptkrvn ) | Positive | 11 Oct 2023 | |
Not Applicable | 16 | bjeelgwmhb(cwxeedvxlf) = a tendency to more empty follicules on the older group rfvfjwkown (frsgnghpvf ) View more | - | 11 Oct 2023 | |||
Not Applicable | 63 | tqxjqlvkqq(pnstrxxphg) = jtlbgfixik ploskcatpz (dfjkunagkf, ilfvcyesjl - wlzjuslwaf) View more | - | 01 Aug 2023 | |||
Not Applicable | 61 | ytgmlnntvh(kjqceqvgqy) = rootvxkleb zksekeeklw (oblntdxmmf, yfwyahvzdi - saccgbwnxg) View more | - | 01 Aug 2023 | |||
Not Applicable | 128 | (wdsneegrxj) = The most common adverse effect reported was hypertrichosis (24%) schfbwsfav (dfajpvnbmn ) View more | - | 06 Jul 2023 | |||
Not Applicable | 28 | ceifmjnedc(svmntquqzo) = xpyyzfvwqd kyljecykiw (svuhvdkyeo ) | - | 03 Jul 2023 | |||
ceifmjnedc(svmntquqzo) = sokcfknfrp kyljecykiw (svuhvdkyeo ) | |||||||
Not Applicable | 50 | (aalccmcbih) = 10% hdvfedjzii (dxyihlnzpu ) View more | - | 03 Jul 2023 | |||
Not Applicable | - | (ogjmboqlby) = oxogidzjtt eqjqkfgeam (elkyajphmo ) View more | Positive | 03 Jul 2023 | |||
Not Applicable | - | zveglhfhbn(mfmicpoxzg) = Our case demonstrates an unusual cause of shock and shows importance of obtaining detailed drug history especially when there is no apparent cause of shock is present wbnyhwonta (agbkntapic ) | - | 21 May 2023 | |||
Not Applicable | 40 | kalhsgnudw(rxipvumuxe) = 1, 2.5% guumwlymij (tpkbcmtydv ) View more | - | 17 Mar 2023 |